Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
 so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may
 allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

 PURPOSE: This phase II trial is studying how well chemotherapy and peripheral stem cell
 transplant work in treating patients with central nervous system cancer.
OBJECTIVES:

 -  Determine the response rate in patients with central nervous system malignancies treated
 with intensive chemotherapy supported by autologous peripheral blood stem cell
 transplantation following surgical resection and/or radiotherapy.

 -  Determine the disease-free survival and overall survival of this patient population
 treated with these regimens.

 -  Determine the toxicity of this high-dose chemotherapy regimen in these patients.

 -  Assess the quality of life of these patients following these treatment regimens.

 OUTLINE: Patients with anaplastic astrocytoma, esthesioneuroblastoma, germ cell tumor, or
 primary neuroectodermal tumor undergo initial surgical resection followed by conventional or
 stereotactic radiotherapy. Patients with germ cell or primary neuroectodermal tumors also
 receive 4 courses of standard chemotherapy comprising cyclophosphamide, etoposide, and
 cisplatin prior to high-dose chemotherapy.

 All patients undergo peripheral blood stem cell or bone marrow harvest followed by high-dose
 chemotherapy consolidation. Patients receive thiotepa IV 3 times daily on days -7 to -3,
 carmustine IV over 1 hour on days -6 to -3, and etoposide IV over 5 hours on days -6 to -3.
 Patients then undergo transplantation on day 0. Filgrastim (G-CSF) is administered
 concurrently with stem cell harvesting and transplantation.

 Patients with recurrent oligodendroglioma or CNS lymphoma who have not received radiotherapy
 at diagnosis undergo conventional radiotherapy 6 weeks after completion of high-dose
 chemotherapy.

 Patients are followed every 2-3 months for 1 year and then annually for 5 years. Quality of
 life is assessed at follow-up.

 PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study over 3 years.
DISEASE CHARACTERISTICS:

 -  Histologically confirmed malignant tumors

 -  Anaplastic astrocytoma

 -  Oligodendroglioma

 -  Germ cell tumor

 -  Medulloblastoma

 -  Primary neuroectodermal tumor

 -  Esthesioneuroblastoma

 -  CNS lymphoma (primary or systemic disease)

 -  Multifocal intracranial disease allowed

 -  No extraneural metastases (except controlled systemic lymphoma)

 -  Pretreatment considerations based on tumor type

 -  Anaplastic astrocytoma:

 -  Recurrent disease

 -  Any treatment at diagnosis allowed (carmustine dose limited to 480 mg/m2)

 -  Chemotherapy not required at recurrence

 -  Oligodendroglioma:

 -  Disease response (at least minor) to conventional chemotherapy OR

 -  Recurrent disease

 -  Esthesioneuroblastoma:

 -  Attempted complete surgical resection

 -  Disease progression after radiotherapy

 -  Response to chemotherapy regimen comprising cyclophosphamide, etoposide, and
 cisplatin

 -  CNS lymphoma:

 -  Disease refractory to methotrexate OR

 -  Failure after initial treatment with methotrexate OR

 -  Considered at high risk for disease relapse despite initial response

 -  Radiographic or pathological confirmation of recurrent disease required

 -  Not eligible for other high priority national or institutional clinical studies

 PATIENT CHARACTERISTICS:

 Age:

 -  18 and over

 Performance status:

 -  ECOG or Zubrod 0-1

 Life expectancy:

 -  Not specified

 Hematopoietic:

 -  Not specified

 Hepatic:

 -  Not specified

 Renal:

 -  Creatinine less than 1.5 times normal

 Cardiovascular:

 -  LVEF at least 45%

 Pulmonary:

 -  DLCO at least 60% predicted OR

 -  Approval of pulmonologist

 Other:

 -  Not pregnant or nursing

 -  HIV negative

 PRIOR CONCURRENT THERAPY:

 Biologic therapy:

 -  Not specified

 Chemotherapy:

 -  See Disease Characteristics

 -  No other concurrent chemotherapy

 Endocrine therapy:

 -  No concurrent anticancer hormonal therapy

 -  No concurrent steroids as antiemetics

 Radiotherapy:

 -  See Disease Characteristics

 Surgery:

 -  See Disease Characteristics

 Other:

 -  No concurrent barbiturates or acetaminophen

 -  Participation in other concurrent supportive care or gene therapy trials allowed